Rigaku Raman Technologies Handheld Raman Analyser Progeny Wins IBO Award for Portable Analytical Instrument Industrial Design
Rigaku Raman Technologies, a leading pioneer of handheld and portable Raman spectrometers, is delighted to announce that its handheld Raman analyser, Progeny has received the Bronze Award for the Portable Analytical Instrument Industrial Design category in the 2014 Instrument Business Outlook (IBO) Design Awards. Progeny represents the new generation in handheld Raman analysis for comprehensive material identification and analysis across applications including raw material identification in the pharmaceutical industry and chemical detection for first responders.
The annual IBO Awards recognise excellence in the industrial design of analytical instruments, portable analytical instruments and laboratory equipment. Judged on innovation, functionality and product features, the winners were selected based on designs that improve product functionality and the end-user experience. In the Portable Analytical Instrument Industrial Design category, winning products were not only chosen for being compact and stylish but also how they address the unique challenges of doing analysis outside of the laboratory.
Progeny is designed to provide superior performance, design and usability for the identification of unknown materials. Weighing just 3.5 lbs, Progeny’s lightweight aluminum housing is sealed against moisture, dust and other potential contaminants to prevent contamination and enables use in any environment with an IP-68 protection rating. The ergonomics of the instrument were carefully considered to provide a comfortable user experience and Progeny’s user-friendly angled display, touchscreen interface provides easy, single-hand use. Compared to other handheld Raman analysers, Progeny provides enhanced performance capabilities for the measurement of colored materials or through dark containers by eliminating fluorescence interference with the use of a unique 1064-nm laser.
Bree Allen, VP and General Manager at Rigaku Raman Technologies, commented on the award win: “We are delighted that Progeny has been recognised with this prestigious award. With Progeny, we exceeded all of our initial expectations by redefining the performance, ruggedness and ease of use that can be experienced when using handheld Raman for material identification. Rigaku Raman is committed to setting new benchmarks in Raman spectroscopy. With Progeny, we have developed a product that we believe will revolutionise what can be achieved with handheld Raman across a multitude of applications.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance